<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058707</url>
  </required_header>
  <id_info>
    <org_study_id>INK128-001</org_study_id>
    <secondary_id>2009-017284-42</secondary_id>
    <secondary_id>U1111-1187-4258</secondary_id>
    <nct_id>NCT01058707</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent
      MLN0128 in Subjects with Advanced Malignancies Followed by an Expansion in Subjects with
      renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 4, 2010</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)and number of Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1: Day 1, 2, 8, 15, and 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of orally administered single agent MLN0128</measure>
    <time_frame>At screening/baseline; Cycle 1: Day 1, 2, 8, 15, and 22; Cycle 2: Day 1, 8, 15, and 22; Cycle 3 and 4: Day 1, 15, and 22; Cycle 5 and thereafter : Day1; and at termination visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters including AUC, Cmax, Cmin, Tmax and t1/2</measure>
    <time_frame>Cycle 1: Day 1, 2 and any day of Days 8-15; Cycle 2: Day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) Assessment of MLN0128</measure>
    <time_frame>Cycle 1 Day 1, 2, 8, 15, and 22; Cycle 2 Day 1, 8, 15, 22; Cycles 3&amp;4 Day 1 &amp; 15; Cycle 5 and Onward Day 1, and at termination visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary anti-tumor activity of MLN0128</measure>
    <time_frame>At screening and thereafter every 2 cycles of treatment. Each cycle is a 28 day cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>MLN0128</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN0128</intervention_name>
    <description>MLN0128 will be administered orally with one of 4 different dosing schedules - once daily (QD), once weekly (QW), once daily for 3 days on;4 days off repeated each week (QDX3d QW), and once daily for 5 days on;2 days off repeated each week (QDX5d QW)</description>
    <arm_group_label>MLN0128</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary written consent

          -  Locally advanced or metastatic solid tumors with the exception of primary brain tumor,
             and have failed standard of care therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Ability to swallow oral medications

          -  For women of child-bearing potential, negative serum or urine pregnancy test within 14
             days prior to the first study drug administration and use of physician-approved method
             of birth control from 30 days prior to 90 days following the last study drug
             administration

          -  Male subjects must be surgically sterile or must agree to use physician-approved
             contraception during the study and for 90 days following the last study drug
             administration

          -  Clinical laboratory values as specified in the protocol

        Additionally, to be eligible for the Dose Expansion portion of the study:

          -  Subjects must have evidence of measurable disease per RECIST version 1.1 by
             radiographic techniques or magnetic resonance imaging

          -  Subjects must have a pathologic diagnosis of advanced or recurrent endometrial
             adenocarcinoma and must have failed at least 1 prior line of standard chemotherapy

          -  Subjects must have a pathologic diagnosis of advanced/metastatic urothelial cancer
             (carcinoma of the bladder, ureter, and/or renal pelvis) and must have failed at least
             1 line of prior therapy in the metastatic/unresectable setting

          -  Subjects must have a pathologic diagnosis of advanced renal cell carcinoma (RCC), with
             histological or cytological confirmation of RCC and must have failed at least 1 prior
             line of anti-VEGF therapy (including but not limited to sunitinib, and/or sorafenib,
             and/or bevacizumab and/or pazopanib, and/or axitinib) and must not have received prior
             therapy with a TORC1 inhibitor (such as temsirolimus or everolimus); or

          -  Subjects must have a pathologic diagnosis of advanced renal cell carcinoma (RCC) and
             must have progressed on treatment with a TORC1 inhibitor (such as temsirolimus or
             everolimus).

        Exclusion Criteria:

          -  Diagnosis of primary brain tumor

          -  Have received prior cancer or other investigational therapy within 2 weeks prior to
             the first administration of study drug

          -  Known impaired cardiac function or clinically significant cardiac disease

          -  Known treatment with systemic corticosteroid within one week prior to the first
             administration of study drug

          -  Diabetes mellitus

          -  HIV infection

          -  Known active cardiovascular disease condition as specified in protocol

          -  Failed to recover from the reversible effects of prior anticancer therapies

          -  Pregnancy (positive serum or urine pregnancy test) or breast feeding

          -  Malabsorption due to prior gastrointestinal (GI) surgery, GI disease

          -  Other clinically significant co-morbidities

        Please note that there are additional inclusion and exclusion criteria. The study center
        will determine if you meet all of the criteria.

        Site personnel will explain the trial in detail and answer any question you may have if you
        do qualify for the study. You can then decide whether or not you wish to participate. If
        you do not qualify for the trial, site personnel will explain the reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors, MLN0128, TORC1/2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

